
Angelo Paci

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4717072/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?. Journal of Hematology and Oncology, 2022, 15, 6.	17.0	17
2	Effects of azacitidine in 93 patients with <i>IDH1/2</i> mutated acute myeloid leukemia/myelodysplastic syndromes: a French retrospective multicenter study. Leukemia and Lymphoma, 2021, 62, 438-445.	1.3	5
3	The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma. Oncologist, 2021, 26, 389-396.	3.7	8
4	Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. Pharmaceuticals, 2021, 14, 272.	3.8	7
5	Multicentric phase II trial of TI E highâ€dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors. Cancer Medicine, 2021, 10, 2250-2258.	2.8	3
6	Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC. Pharmaceuticals, 2021, 14, 927.	3.8	3
7	Late phase 1 studies: concepts and outcomes. Lancet Oncology, The, 2021, 22, e446-e455.	10.7	2
8	Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study. ESMO Open, 2021, 6, 100312.	4.5	17
9	Antidrug Antibodies Against Immune Checkpoint Blockers: Impairment of Drug Efficacy or Indication of Immune Activation?. Clinical Cancer Research, 2020, 26, 787-792.	7.0	44
10	Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma. Neuro-Oncology Advances, 2020, 2, vdaa075.	0.7	2
11	Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation. Expert Review of Precision Medicine and Drug Development, 2020, 5, 421-428.	0.7	3
12	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biology of Blood and Marrow Transplantation, 2020, 26, e235-e236.	2.0	0
13	New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning. Pediatric Blood and Cancer, 2020, 67, e28603.	1.5	7
14	Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. , 2020, 8, e000916.		1
15	Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3758.	3.7	4
16	1166MO Clinical evaluation of serum succinate levels as a new biomarker in SDH-related paragangliomas and pheochromocytomas. Annals of Oncology, 2020, 31, S773-S774.	1.2	2
17	727P Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study. Annals of Oncology, 2020, 31, S569-S570.	1.2	0
18	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2020, 38, 2762-2772.	1.6	80

#	Article	IF	CITATIONS
19	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies. European Journal of Cancer, 2020, 128, 119-128.	2.8	50
20	Pharmacokinetics/Pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what's new?. European Journal of Cancer, 2020, 128, 103-106.	2.8	7
21	Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugatesÂand bispecific T-cell engagers. European Journal of Cancer, 2020, 128, 107-118.	2.8	36
22	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nature Communications, 2020, 11, 2168.	12.8	231
23	Prodrugs as drug delivery system in oncology. Cancer Chemotherapy and Pharmacology, 2019, 84, 937-958.	2.3	23
24	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. Biology of Blood and Marrow Transplantation, 2019, 25, 1890-1897.	2.0	19
25	Biodegradable Pickering emulsions of Lipiodol for liver trans-arterial chemo-embolization. Acta Biomaterialia, 2019, 87, 177-186.	8.3	30
26	Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Critical Reviews in Oncology/Hematology, 2019, 141, 112-124.	4.4	11
27	Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. International Journal of Oncology, 2019, 54, 2149-2156.	3.3	8
28	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. Nature Communications, 2019, 10, 1486.	12.8	189
29	Intestinal bacterial β-glucuronidase as a possible predictive biomarker of irinotecan-induced diarrhea severity. , 2019, 199, 1-15.		59
30	MA21.09 Tyrosine Kinase Inhibitors' Plasma Concentration and Oncogene-Addicted Advanced Non-Small Lung Cancer (aNSCLC) Resistance. Journal of Thoracic Oncology, 2019, 14, S337-S338.	1.1	2
31	1,1-Diheterocyclic Ethylenes Derived from Quinaldine and Carbazole as New Tubulin-Polymerization Inhibitors: Synthesis, Metabolism, and Biological Evaluation. Journal of Medicinal Chemistry, 2019, 62, 1902-1916.	6.4	43
32	Mutational profiling of isolated myeloid sarcomas and utility of serum 2HG as biomarker of IDH1/2 mutations. Leukemia, 2018, 32, 2008-2081.	7.2	18
33	Pickering-Emulsion for Liver Trans-Arterial Chemo-Embolization with Oxaliplatin. CardioVascular and Interventional Radiology, 2018, 41, 781-788.	2.0	28
34	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. European Journal of Cancer, 2018, 91, 56-67.	2.8	8
35	Curcumin dietary supplements and everolimus-based cancer treatment. Annals of Oncology, 2018, 29, 287-288.	1.2	7
36	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase–mutated intrahepatic cholangiocarcinomas. European Journal of Cancer, 2018, 90, 83-91.	2.8	28

Angelo Paci

#	Article	IF	CITATIONS
37	What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum?. Bioanalysis, 2018, 10, 723-735.	1.5	12
38	Serum 2-Hydroxyglutarate in Angioimmunoblastic T Cell Lymphomas: A New Marker for IDH2 Mutation Detection and Monitoring. Blood, 2018, 132, 2898-2898.	1.4	1
39	AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations. Cancer Discovery, 2017, 7, 478-493.	9.4	350
40	Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient. Annales D'Endocrinologie, 2017, 78, 67-69.	1.4	4
41	Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours. European Journal of Cancer, 2017, 81, 81-89.	2.8	11
42	Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies. International Journal of Pharmaceutics, 2017, 532, 748-756.	5.2	1
43	Busulfan after HSCT in children and young adults. Lancet Haematology,the, 2017, 4, e103.	4.6	2
44	Stabilization Improves Theranostic Properties of Lipiodol®-Based Emulsion During Liver Trans-arterial Chemo-embolization in a VX2 Rabbit Model. CardioVascular and Interventional Radiology, 2017, 40, 907-913.	2.0	12
45	Colchicine is an active treatment for everolimus-induced oral ulcers. European Journal of Cancer, 2017, 87, 209-211.	2.8	4
46	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research, 2017, 23, 7171-7179.	7.0	15
47	Ultrasound-induced mild hyperthermia improves the anticancer efficacy of both Taxol® and paclitaxel-loaded nanocapsules. Journal of Controlled Release, 2017, 264, 219-227.	9.9	36
48	Safety, tolerabilityÂand antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study. European Journal of Cancer, 2017, 83, 194-202.	2.8	14
49	Prevention of 5-fluorouracil–induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing. Seminars in Oncology, 2017, 44, 159-160.	2.2	5
50	Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC. International Journal of Pharmaceutics, 2017, 531, 143-152.	5.2	19
51	Parameters for Stable Water-in-Oil Lipiodol Emulsion for Liver Trans-Arterial Chemo-Eembolization. CardioVascular and Interventional Radiology, 2017, 40, 1927-1932.	2.0	30
52	Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Investigational New Drugs, 2017, 35, 247-249.	2.6	8
53	A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents. Cancer Research, 2017, 77, 557-565.	0.9	10
54	Individualized Pazopanib Dosing—Letter. Clinical Cancer Research, 2016, 22, 6298-6298.	7.0	4

#	Article	IF	CITATIONS
55	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 15084-15089.	7.1	96
56	Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1022, 290-297.	2.3	30
57	Busulfan–Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed–unexposed study evaluating the clinical impact of the order of drug administration. Bone Marrow Transplantation, 2016, 51, 1265-1267.	2.4	6
58	Familial hematological malignancies: new IDH2 mutation. Annals of Hematology, 2016, 95, 1943-1947.	1.8	7
59	Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer. British Journal of Cancer, 2016, 115, 549-552.	6.4	11
60	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biology of Blood and Marrow Transplantation, 2016, 22, 1915-1925.	2.0	130
61	Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice. Pharmaceutical Research, 2016, 33, 1913-1922.	3.5	15
62	Antineoplastic busulfan encapsulated in a metal organic framework nanocarrier: first in vivo results. Journal of Materials Chemistry B, 2016, 4, 585-588.	5.8	34
63	Dyslipidemia causes overestimation of plasma mitotane measurements. Endocrinology, Diabetes and Metabolism Case Reports, 2016, 2016, 150135.	0.5	3
64	Nilotinib versus imatinib for GIST. Lancet Oncology, The, 2015, 16, e311.	10.7	2
65	Safety and Efficacy Compared between Irinotecan-Loaded Microspheres HepaSphere and DC Bead in a Model of VX2 Liver Metastases in the Rabbit. Journal of Vascular and Interventional Radiology, 2015, 26, 1067-1075.e3.	0.5	17
66	Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2890-2898.	3.6	30
67	Simultaneous quantification of preactivated ifosfamide derivatives and of 4-hydroxyifosfamide by high performance liquid chromatography–tandem mass spectrometry in mouse plasma and its application to a pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2015. 992. 30-35.	2.3	3
68	Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model. Annals of Oncology, 2015, 26, 1500-1504.	1.2	24
69	A case of melphalan sustained accumulation in an 80-year old patient. International Journal of Clinical Pharmacy, 2015, 37, 984-987.	2.1	4
70	Stability of Melphalan in 0.9Â% Sodium Chloride Solutions Prepared in Polyvinyl Chloride Bags for Intravenous Injection. Drugs in R and D, 2015, 15, 253-259.	2.2	10
71	Preactivated Oxazaphosphorines Designed for Isophosphoramide Mustard Delivery as Bulk Form or Nanoassemblies: Synthesis and Proof of Concept. Journal of Medicinal Chemistry, 2015, 58, 705-717.	6.4	14
72	Pharmacokinetic interaction involving fenofibrate and everolimus. Annals of Oncology, 2015, 26, 248-249.	1.2	14

Angelo Paci

#	Article	IF	CITATIONS
73	Serum 2-Hydroxyglutarate Allows Early Prediction of Response during Induction Chemotherapy in Acute Myeloid Leukemia with IDH Mutation. Blood, 2015, 126, 3833-3833.	1.4	1
74	Serum 2-Hydroxyglutarate Level Can Predict IDH2 Mutation in Myeloid Sarcoma. Blood, 2015, 126, 3835-3835.	1.4	3
75	The Lack of Antitumor Effects of 0,p′DDA Excludes Its Role as an Active Metabolite of Mitotane for Adrenocortical Carcinoma Treatment. Hormones and Cancer, 2014, 5, 312-323.	4.9	19
76	Vemurafenib in pediatric patients with <scp><i>BRAFV</i></scp> <i>600E</i> mutated highâ€grade gliomas. Pediatric Blood and Cancer, 2014, 61, 1101-1103.	1.5	125
77	Efficacy and safety of gefitinib during pregnancy: Case report and literature review. Lung Cancer, 2014, 85, 481-484.	2.0	29
78	Stability of Etoposide Solutions in Disposable Infusion Devices for Day Hospital Cancer Practices. Drugs in R and D, 2014, 14, 13-23.	2.2	4
79	Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. European Journal of Cancer, 2014, 50, 2020-2036.	2.8	248
80	Therapeutic drug monitoring in cancer – Are we missing a trick?. European Journal of Cancer, 2014, 50, 2005-2009.	2.8	79
81	Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics. European Journal of Cancer, 2014, 50, 2010-2019.	2.8	205
82	Pharmacokinetics/Pharmacodynamic Relationship in Busulfan Conditioning Regimen: Results from a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation. Blood, 2014, 124, 425-425.	1.4	1
83	Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib. European Journal of Drug Metabolism and Pharmacokinetics, 2013, 38, 149-157.	1.6	10
84	Physico-Chemical Stability of Busulfan in Injectable Solutions in Various Administration Packages. Drugs in R and D, 2013, 13, 87-94.	2.2	15
85	Pharmacology of dimethanesulfonate alkylating agents: busulfan and treosulfan. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 333-347.	3.3	55
86	First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient. Lung Cancer, 2013, 80, 113-114.	2.0	4
87	Body Composition Variation and Impact of Low Skeletal Muscle Mass in Patients With Advanced Medullary Thyroid Carcinoma Treated With Vandetanib: Results From a Placebo-Controlled Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2401-2408.	3.6	88
88	Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients. Oncolmmunology, 2013, 2, e23079.	4.6	18
89	Phase I clinical trial combining imatinib mesylate and IL-2. Oncolmmunology, 2013, 2, e23080.	4.6	29
90	Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocrine-Related Cancer, 2013, 20, 371-381.	3.1	75

#	Article	IF	CITATIONS
91	Population Pharmacokinetics of Busulfan in Children–Letter: Figure 1 Clinical Cancer Research, 2012, 18, 2715-2716.	7.0	4
92	Pharmacokinetic Behavior and Appraisal of Intravenous Busulfan Dosing in Infants and Older Children. Therapeutic Drug Monitoring, 2012, 34, 198-208.	2.0	76
93	High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. European Journal of Endocrinology, 2012, 166, 261-268.	3.7	50
94	Performance of alfentanil target-controlled infusion in normal and morbidly obese female patients. British Journal of Anaesthesia, 2012, 109, 551-560.	3.4	12
95	Hyperthermic Pelvic Perfusion With Tumor Necrosis Factor-α for Locally Advanced Cancers. Annals of Surgery, 2012, 255, 281-286.	4.2	23
96	Safety and quality assurance of chemotherapeutic preparations in a hospital production unit: Acceptance sampling plan and economic impact. Journal of Oncology Pharmacy Practice, 2012, 18, 163-170.	0.9	7
97	Off-patent Oral Oncology Drugs for Kids (O3K FP7-project): From bedside to PUMA. International Journal of Pharmaceutics, 2012, 435, 148-150.	5.2	1
98	Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: Good tolerance profile and efficacy in rhabdomyosarcoma – A report from the Société Française des Cancers et leucémies de l'Enfant et l'adolescent (SFCE). European Journal of Cancer, 2012, 48, 2409-2416.	: de ^{2.8}	57
99	Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. European Journal of Cancer, 2012, 48, 3063-3072.	2.8	54
100	Comparative transplacental transfer of taxanes using the human perfused cotyledon placental model. American Journal of Obstetrics and Gynecology, 2012, 207, 514.e1-514.e7.	1.3	31
101	Irinotecan Loaded in Eluting Beads: Preclinical Assessment in a Rabbit VX2 Liver Tumor Model. CardioVascular and Interventional Radiology, 2012, 35, 1448-1459.	2.0	36
102	Natural history, management and pharmacokinetics of Everolimus-induced-oral ulcers: Insights into compliance issues. European Journal of Cancer, 2011, 47, 2249-2255.	2.8	42
103	A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. International Journal of Pharmaceutics, 2011, 414, 285-297.	5.2	16
104	Quantification of dimethyl-ifosfamide and its N-deschloropropylated metabolites in mouse plasma by liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 743-750.	2.3	4
105	Microbiological and Physicochemical Stability of Oxycodone Hydrochloride Solutions forÂPatient-Controlled Delivery Systems. Journal of Pain and Symptom Management, 2010, 40, 87-94.	1.2	6
106	Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer, 2010, 17, 797-807.	3.1	52
107	Phase I study of topotecan in combination with temozolomide (TOTEM) in relapsed or refractory paediatric solid tumours. European Journal of Cancer, 2010, 46, 2763-2770.	2.8	20
108	Oxazaphosphorines: new therapeutic strategies for an old class of drugs. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 919-938.	3.3	65

#	Article	IF	CITATIONS
109	Screening for Potential Covariates Influencing the Pharmacokinetics of Intravenous Busulfan: Results From a Large Pediatric Cohort Undergoing Hematopoietic Stem-Cell Transplantation. Blood, 2010, 116, 1811-1811.	1.4	0
110	New Ifosfamide Analogs Designed for Lower Associated Neurotoxicity and Nephrotoxicity with Modified Alkylating Kinetics Leading to Enhanced in Vitro Anticancer Activity. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 598-609.	2.5	14
111	Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry. International Journal of Pharmaceutics, 2009, 379, 235-243.	5.2	16
112	Acoustic characterization of a new trisacryl contrast agent. Part II: Flow phantom study and in vivo quantification. Ultrasonics, 2008, 48, 26-34.	3.9	2
113	Acoustic characterization of a new trisacryl contrast agent. Part I: In vitro study. Ultrasonics, 2008, 48, 16-25.	3.9	8
114	Squalenoylation Favorably Modifies the in Vivo Pharmacokinetics and Biodistribution of Gemcitabine in Mice. Drug Metabolism and Disposition, 2008, 36, 1570-1577.	3.3	86
115	Busulphan-loaded long-circulating nanospheres, a very attractive challenge for both galenists and pharmacologists. Journal of Microencapsulation, 2007, 24, 715-730.	2.8	7
116	Induction of Clutathione Synthesis Explains Pharmacodynamics of High-Dose Busulfan in Mice and Highlights Putative Mechanisms of Drug Interaction. Drug Metabolism and Disposition, 2007, 35, 306-314.	3.3	17
117	Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2237-2240.	2.2	33
118	Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. International Journal of Pharmaceutics, 2007, 344, 62-70.	5.2	26
119	Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography–tandem mass spectrometry in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 71-78.	2.3	26
120	Elevated Plasma Ferritin and Busulfan Pharmacodynamics During High-dose Chemotherapy Regimens in Children with Malignant Solid Tumors. Clinical Pharmacology and Therapeutics, 2007, 82, 402-409.	4.7	14
121	Application of an acceptance sampling plan for post-production quality control of chemotherapeutic batches in an hospital pharmacy. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 64, 92-98.	4.3	18
122	Evaluation of the pharmacokinetic profile and analgesic efficacy of oral morphine after total hip arthroplasty. European Journal of Anaesthesiology, 2006, 23, 748-754.	1.7	19
123	Near infrared spectroscopy and process analytical technology to master the process of busulfan paediatric capsules in a university hospital. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 1171-1178.	2.8	31
124	Liquid chromatography–tandem mass spectrometry assay of reduced and oxidized glutathione and main precursors in mice liver. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 832, 67-74.	2.3	58
125	Microbiological and Physicochemical Stability of Fentanyl and Sufentanil Solutions for Patient-Controlled Delivery Systems. Journal of Pain and Symptom Management, 2006, 32, 90-97.	1.2	6
126	Pharmacokinetics, Metabolism, and Routes of Excretion of Intravenous Irofulven in Patients with Advanced Solid Tumors. Drug Metabolism and Disposition, 2006, 34, 1918-1926.	3.3	13

#	Article	IF	CITATIONS
127	In Vitro Echogenicity Characterization of Poly[lactide-coglycolide] (PLGA) Microparticles and Preliminary In Vivo Ultrasound Enhancement Study for Ultrasound Contrast Agent Application. Investigative Radiology, 2005, 40, 536-544.	6.2	15
128	Quality control and stability study using HPTLC: applications to cyclophosphamide in various pharmaceutical products. Journal of Pharmaceutical and Biomedical Analysis, 2005, 38, 180-185.	2.8	15
129	Fluorescence detection combined with either HPLC or HPTLC for pharmaceutical quality control in a hospital chemotherapy production unit: Application to camptothecin derivatives. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 581-586.	2.8	30
130	Liquid chromatography–mass spectrometry assay for quantitation of ifosfamide and its -deschloroethylated metabolites in rat microsomal medium. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 820, 251-259.	2.3	12
131	E.F.P. – European Fellowship for Pharmacists Promoting Clinical Pharmacy in Europe. International Journal of Clinical Pharmacy, 2005, 27, 278-278.	1.4	0
132	Microbial growth tests in anti-neoplastic injectable solutions. Journal of Oncology Pharmacy Practice, 2005, 11, 7-12.	0.9	6
133	High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products. Journal of Pharmaceutical and Biomedical Analysis, 2004, 34, 525-530.	2.8	17
134	Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Medical Science Monitor, 2004, 10, CR209-12.	1.1	33
135	Identification and quantitation of antineoplastic compounds in chemotherapeutic infusion bags by use of HPTLC: application to the vinca-alkaloids. Journal of Pharmaceutical and Biomedical Analysis, 2003, 30, 1603-1610.	2.8	34
136	Contribution of high-performance thin-layer chromatography to a pharmaceutical quality assurance programme in a hospital chemotherapy manufacturing unit. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 56, 445-451.	4.3	19
137	Human Pharmacokinetic Study of Heated Intraperitoneal Oxaliplatin in Increasingly Hypotonic Solutions after Complete Resection of Peritoneal Carcinomatosis. Oncology, 2002, 63, 346-352.	1.9	89
138	Dual-mode gradient HPLC procedure for the simultaneous determination of chloroquine and proguanil. Journal of Pharmaceutical and Biomedical Analysis, 2002, 27, 1-7.	2.8	21
139	Separation methods for alkylating antineoplastic compounds. Biomedical Applications, 2001, 764, 255-287.	1.7	15
140	Anodic Oxidation of Ifosfamide and Cyclophosphamide. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 1347-1349.	2.2	34
141	Synthesis of sideâ€chainâ€substituted ifosfamide analogs. Journal of Heterocyclic Chemistry, 2001, 38, 1131-1134.	2.6	6
142	Quantitative high-performance liquid chromatographic determination of acrolein in plasma after derivatization with Luminarin® 3. Biomedical Applications, 2000, 739, 239-246.	1.7	19